MA46690A - Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 - Google Patents
Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2Info
- Publication number
- MA46690A MA46690A MA046690A MA46690A MA46690A MA 46690 A MA46690 A MA 46690A MA 046690 A MA046690 A MA 046690A MA 46690 A MA46690 A MA 46690A MA 46690 A MA46690 A MA 46690A
- Authority
- MA
- Morocco
- Prior art keywords
- triazolo
- pyrimidine compounds
- pde2 inhibitors
- pde2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16196936 | 2016-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46690A true MA46690A (fr) | 2019-09-11 |
Family
ID=57223577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046690A MA46690A (fr) | 2016-11-02 | 2017-10-31 | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11319321B2 (fr) |
EP (1) | EP3535268B1 (fr) |
JP (1) | JP7018944B2 (fr) |
KR (1) | KR20190067788A (fr) |
CN (1) | CN109890824B (fr) |
AU (1) | AU2017353313C1 (fr) |
BR (1) | BR112019008604A2 (fr) |
CA (1) | CA3038913A1 (fr) |
EA (1) | EA039847B1 (fr) |
ES (1) | ES2912264T3 (fr) |
MA (1) | MA46690A (fr) |
MX (1) | MX2019005123A (fr) |
WO (1) | WO2018083101A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6872541B2 (ja) | 2015-11-02 | 2021-05-19 | ヤンセン ファーマシューティカ エヌ.ベー. | [1,2,4]トリアゾロ[1,5−a]ピリミジン−7−イル化合物 |
EP3535268B1 (fr) | 2016-11-02 | 2022-02-09 | Janssen Pharmaceutica NV | Composés de [1,2,4]triazolo[1,5-a]pyrimidine comme inhibiteurs de pde2 |
JP7021208B2 (ja) * | 2016-11-02 | 2022-02-16 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン化合物 |
SG11201903892UA (en) | 2016-11-02 | 2019-05-30 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
JP2020509004A (ja) * | 2017-02-27 | 2020-03-26 | ヤンセン ファーマシューティカ エヌ.ベー. | Oga阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている[1,2,4]−トリアゾロ[1,5−a]−ピリミジニル誘導体 |
CN115960101A (zh) * | 2022-12-30 | 2023-04-14 | 海南大学 | 7-氧代-4,5,6,7-四氢吡唑并吡啶酰胺类化合物及其制备方法和应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
EA200000768A1 (ru) | 1998-01-27 | 2001-06-25 | Эвентис Фармасьютикалз Продактс Инк. | ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
ATE425967T1 (de) | 2002-10-03 | 2009-04-15 | Vertex Pharma | Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten |
EP1644003A1 (fr) | 2003-06-04 | 2006-04-12 | Vernalis (Cambridge) Limited | Triazolo ´1,5-a!pyrimidines et leur utilisation en medecine |
EP1781659B1 (fr) | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Derives de triazolopyrimidine en tant qu'inhibiteurs de glycogene synthase kinase 3 |
JP4707560B2 (ja) | 2003-12-29 | 2011-06-22 | Msd株式会社 | 新規2−ヘテロアリール置換ベンズイミダゾール誘導体 |
TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体 |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
WO2007113136A1 (fr) | 2006-03-30 | 2007-10-11 | Basf Aktiengesellschaft | Utilisation de triazolopyrimidines substituées dans la lutte contre des champignons phytopathogènes |
JP2007332061A (ja) | 2006-06-14 | 2007-12-27 | Nippon Kayaku Co Ltd | 新規ピラゾロ[1,5−a]ピリミジン誘導体及びその用途 |
US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
WO2008048914A1 (fr) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Composés qui modulent le récepteur cb2 |
US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
JP2010065024A (ja) * | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
ES2650744T3 (es) | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
KR101548443B1 (ko) | 2011-02-23 | 2015-08-28 | 화이자 인코포레이티드 | 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진 |
EP2723744B1 (fr) | 2011-06-27 | 2016-03-23 | Janssen Pharmaceutica, N.V. | Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]-quinoxaline |
US9682953B2 (en) | 2011-09-23 | 2017-06-20 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
JP6418950B2 (ja) | 2012-03-09 | 2018-11-07 | レクシコン ファーマシューティカルズ インコーポレイテッド | ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法 |
US9676757B2 (en) | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
ME03472B (fr) | 2014-03-19 | 2020-01-20 | Boehringer Ingelheim Int | Inhibiteurs de sik de type hétéroaryle |
HRP20212035T1 (hr) * | 2014-04-23 | 2022-04-01 | Dart Neuroscience Llc | Pripravci koji sadrže supstituirane [1,2,4]triazolo[1,5-a]pirimidin-7-il spojeve kao inhibitore pde2 |
CR20160493A (es) | 2014-04-25 | 2016-12-16 | Pfizer | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 |
CN105566321B (zh) | 2014-10-29 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
TWI530688B (zh) | 2014-11-18 | 2016-04-21 | 彭顯智 | 製備微奈米探針設備及方法 |
WO2016107602A1 (fr) | 2015-01-01 | 2016-07-07 | 成都贝斯凯瑞生物科技有限公司 | Dérivés hétérocycliques d'azote substitués et leur utilisation |
WO2016145614A1 (fr) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2 |
WO2017000276A1 (fr) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2 |
WO2017000277A1 (fr) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclo-composés de triazole substitués utilisés en tant qu'inhibiteurs de pde2 |
US20180305334A1 (en) | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
JP6872541B2 (ja) | 2015-11-02 | 2021-05-19 | ヤンセン ファーマシューティカ エヌ.ベー. | [1,2,4]トリアゾロ[1,5−a]ピリミジン−7−イル化合物 |
WO2017157882A1 (fr) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Inhibiteurs de la voie de biosynthèse de la sérine |
JP7021208B2 (ja) | 2016-11-02 | 2022-02-16 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン化合物 |
SG11201903892UA (en) | 2016-11-02 | 2019-05-30 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
EP3535268B1 (fr) | 2016-11-02 | 2022-02-09 | Janssen Pharmaceutica NV | Composés de [1,2,4]triazolo[1,5-a]pyrimidine comme inhibiteurs de pde2 |
CA3044762A1 (fr) | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Composes inhibiteurs d'oga bicyclique |
-
2017
- 2017-10-31 EP EP17797113.2A patent/EP3535268B1/fr active Active
- 2017-10-31 BR BR112019008604A patent/BR112019008604A2/pt active Search and Examination
- 2017-10-31 CA CA3038913A patent/CA3038913A1/fr active Pending
- 2017-10-31 WO PCT/EP2017/077918 patent/WO2018083101A1/fr unknown
- 2017-10-31 CN CN201780067757.4A patent/CN109890824B/zh active Active
- 2017-10-31 MA MA046690A patent/MA46690A/fr unknown
- 2017-10-31 US US16/346,745 patent/US11319321B2/en active Active
- 2017-10-31 JP JP2019523012A patent/JP7018944B2/ja active Active
- 2017-10-31 ES ES17797113T patent/ES2912264T3/es active Active
- 2017-10-31 AU AU2017353313A patent/AU2017353313C1/en not_active Ceased
- 2017-10-31 EA EA201991094A patent/EA039847B1/ru unknown
- 2017-10-31 MX MX2019005123A patent/MX2019005123A/es unknown
- 2017-10-31 KR KR1020197009775A patent/KR20190067788A/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2018083101A1 (fr) | 2018-05-11 |
CN109890824A (zh) | 2019-06-14 |
MX2019005123A (es) | 2019-06-20 |
US11319321B2 (en) | 2022-05-03 |
BR112019008604A2 (pt) | 2019-07-09 |
JP7018944B2 (ja) | 2022-02-14 |
US20200055858A1 (en) | 2020-02-20 |
ES2912264T3 (es) | 2022-05-25 |
EP3535268B1 (fr) | 2022-02-09 |
EA201991094A1 (ru) | 2019-09-30 |
CN109890824B (zh) | 2022-05-24 |
AU2017353313A1 (en) | 2019-04-18 |
CA3038913A1 (fr) | 2018-05-11 |
AU2017353313C1 (en) | 2022-06-09 |
AU2017353313B2 (en) | 2021-09-16 |
JP2019532990A (ja) | 2019-11-14 |
EA039847B1 (ru) | 2022-03-18 |
EP3535268A1 (fr) | 2019-09-11 |
KR20190067788A (ko) | 2019-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53675A (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
CL2019000942A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
FR22C1006I2 (fr) | Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak) | |
DK3478682T3 (da) | [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser | |
HK1259623A1 (zh) | 作爲irak4調節劑的吡唑並[1,5a]嘧啶衍生物 | |
HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物 | |
HK1245764A1 (zh) | 3-取代的5-氨基-6h-噻唑並[4,5-d]嘧啶-2,7-二酮化合物 | |
IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
MA46690A (fr) | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 | |
SG11201801365YA (en) | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | |
DK3418281T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme | |
MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
MA43021A (fr) | Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1 | |
MA52593A (fr) | 1h-pyrazolo[4,3-b]pyridines en tant qu'inhibiteurs pde1 | |
ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
EP3328840A4 (fr) | Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2 | |
IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
EP3313852A4 (fr) | Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2 | |
DK3419979T3 (da) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser | |
MA41174A (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
MA46463A (fr) | Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret | |
TH1601003657A (th) | อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส |